| 1 |
Decitabine FDA Label
|
| 2 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6805).
|
| 3 |
Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
|
| 4 |
Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
|
| 5 |
ClinicalTrials.gov (NCT01001143) Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)
|
| 6 |
ClinicalTrials.gov (NCT02488408) A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
|
| 7 |
ClinicalTrials.gov (NCT00703300) Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
|
| 8 |
ClinicalTrials.gov (NCT00037817) Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
|
| 9 |
ClinicalTrials.gov (NCT02839694) Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy
|
| 10 |
ClinicalTrials.gov (NCT00903760) Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)
|
| 11 |
ClinicalTrials.gov (NCT00075010) Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes
|
| 12 |
ClinicalTrials.gov (NCT01498445) An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
|
| 13 |
ClinicalTrials.gov (NCT00079378) Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
| 14 |
ClinicalTrials.gov (NCT00002832) Decitabine and Peripheral Stem Cell Transplantation in Treating Patients Who Have Relapsed Following Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
|
| 15 |
ClinicalTrials.gov (NCT01546038) A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
| 16 |
ClinicalTrials.gov (NCT00114257) Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
|
| 17 |
ClinicalTrials.gov (NCT00275080) Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia
|
| 18 |
ClinicalTrials.gov (NCT00561912) Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
|
| 19 |
ClinicalTrials.gov (NCT05230368) Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load
|
| 20 |
ClinicalTrials.gov (NCT01893320) Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
|
| 21 |
ClinicalTrials.gov (NCT02847000) p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
|
| 22 |
ClinicalTrials.gov (NCT02954653) A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
|
| 23 |
ClinicalTrials.gov (NCT03113071) Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
|
| 24 |
ClinicalTrials.gov (NCT05524857) Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
|
| 25 |
ClinicalTrials.gov (NCT02685228) Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer
|
| 26 |
ClinicalTrials.gov (NCT02343939) Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
|
| 27 |
ClinicalTrials.gov (NCT02141477) Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
|
| 28 |
ClinicalTrials.gov (NCT02564536) Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
|
| 29 |
ClinicalTrials.gov (NCT00691938) LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
|
| 30 |
ClinicalTrials.gov (NCT01352650) Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
|
| 31 |
ClinicalTrials.gov (NCT02076191) Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
|
| 32 |
ClinicalTrials.gov (NCT03974217) Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
|
| 33 |
ClinicalTrials.gov (NCT02878785) Decitabine and Talazoparib in Untreated AML and R/R AML
|
| 34 |
ClinicalTrials.gov (NCT00715793) Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma
|
| 35 |
ClinicalTrials.gov (NCT03013998) Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
|
| 36 |
ClinicalTrials.gov (NCT02203773) Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
|
| 37 |
ClinicalTrials.gov (NCT03844815) Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
|
| 38 |
ClinicalTrials.gov (NCT02190695) Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
|
| 39 |
ClinicalTrials.gov (NCT05766514) Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
|
| 40 |
ClinicalTrials.gov (NCT00778375) Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
|
| 41 |
ClinicalTrials.gov (NCT01993641) Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
|
| 42 |
ClinicalTrials.gov (NCT04051996) GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
|
| 43 |
ClinicalTrials.gov (NCT02084563) Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
|
| 44 |
ClinicalTrials.gov (NCT01607645) Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS
|
| 45 |
ClinicalTrials.gov (NCT01846624) Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
|
| 46 |
ClinicalTrials.gov (NCT04097470) Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients
|
| 47 |
ClinicalTrials.gov (NCT02029417) Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
|
| 48 |
ClinicalTrials.gov (NCT02469415) Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
| 49 |
ClinicalTrials.gov (NCT02532010) Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML
|
| 50 |
ClinicalTrials.gov (NCT02085408) Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
|
| 51 |
ClinicalTrials.gov (NCT02985372) Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia
|
| 52 |
ClinicalTrials.gov (NCT03252457) Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
|
| 53 |
ClinicalTrials.gov (NCT04229979) GPS Compared With BAT in AML CR2/CR2p. U.S. National Institutes of Health.
|
|
|
|
|
|
|
